Patents by Inventor Stephen J. Farr

Stephen J. Farr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulation for inhibiting formation of 5-HTagonists and methods of using same
    Patent number: 11786487
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: October 17, 2023
    Assignee: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. Farr, Brooks Boyd
  • Formulation for inhibiting formation of 5-HTagonists and methods of using same
    Patent number: 11759440
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: September 19, 2023
    Assignee: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. Farr, Brooks Boyd
  • Metabolism resistant fenfluramine analogs and methods of using the same
    Patent number: 11673852
    Abstract: Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: June 13, 2023
    Assignee: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. Farr, Brooks M. Boyd
  • FENFLURAMINE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH SPREADING DEPOLARIZATION
    Publication number: 20230165810
    Abstract: Provided are methods of inhibiting spreading depolarization in a subject by administering a sigma-1 agonist or a sigma-1 positive modulator to the subject. In some cases the subject is administered fenfluramine as the sigma-1 positive modulator. In some cases, the subject has been diagnosed with epilepsy, traumatic brain injury, migraines, stroke, ischemic attacks, hypoxia or an increased risk of sudden unexpected death in epilepsy (SUDEP), or a combination thereof.
    Type: Application
    Filed: November 22, 2022
    Publication date: June 1, 2023
    Applicants: ZOGENIX INTERNATIONAL LIMITED, BAYLOR COLLEGE OF MEDICINE
    Inventors: Bradley S. GALER, Stephen J. FARR, Thaddeus Cromwell REEDER, Jeff NOEBELS
  • METABOLISM RESISTANT FENFLURAMINE ANALOGS AND METHODS OF USING THE SAME
    Publication number: 20220289663
    Abstract: Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.
    Type: Application
    Filed: April 5, 2022
    Publication date: September 15, 2022
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, Brooks M. BOYD
  • Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
    Patent number: 11406606
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: August 9, 2022
    Assignee: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. Farr, Brooks Boyd
  • METHODS OF TREATING DOOSE SYNDROME USING FENFLURAMINE
    Publication number: 20220226262
    Abstract: A method of treating and/or preventing symptoms of Doose syndrome in a patient such as a patient previously diagnosed with Doose syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Doose syndrome patients are treated at a preferred dose of less than about 10.0 to about 0.01 mg/kg/day.
    Type: Application
    Filed: April 5, 2022
    Publication date: July 21, 2022
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Brooks BOYD, Stephen J. FARR, Bradley GALER
  • Metabolism resistant fenfluramine analogs and methods of using the same
    Patent number: 11325882
    Abstract: Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: May 10, 2022
    Assignee: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. Farr, Brooks M. Boyd
  • Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same
    Publication number: 20220125743
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Application
    Filed: January 7, 2022
    Publication date: April 28, 2022
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, Brooks BOYD
  • Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same
    Publication number: 20210393550
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Application
    Filed: July 1, 2021
    Publication date: December 23, 2021
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, Brooks BOYD
  • Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same
    Publication number: 20210267916
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 2, 2021
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, BROOKS BOYD
  • Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
    Patent number: 11040018
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: June 22, 2021
    Assignee: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. Farr, Brooks Boyd
  • METABOLISM RESISTANT FENFLURAMINE ANALOGS AND METHODS OF USING THE SAME
    Publication number: 20200331844
    Abstract: Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.
    Type: Application
    Filed: May 8, 2020
    Publication date: October 22, 2020
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, Brooks M. BOYD
  • METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE
    Publication number: 20200253895
    Abstract: A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Lennox Syndrome patients are treated at a preferred dose of less than about 2.0 to about 0.01 mg/kg/day.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 13, 2020
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, Bradley S. GALER
  • Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same
    Publication number: 20200246281
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Application
    Filed: March 6, 2020
    Publication date: August 6, 2020
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, BROOKS BOYD
  • METHODS OF TREATING DOOSE SYNDROME USING FENFLURAMINE
    Publication number: 20200170965
    Abstract: A method of treating and/or preventing symptoms of Doose syndrome in a patient such as a patient previously diagnosed with Doose syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Doose syndrome patients are treated at a preferred dose of less than about 10.0 to about 0.01 mg/kg/day.
    Type: Application
    Filed: May 4, 2018
    Publication date: June 4, 2020
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Brooks BOYD, Stephen J. FARR, Bradley GALER
  • Formulation for inhibiting formation of 5-HTagonists and methods of using same
    Patent number: 10603290
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: March 31, 2020
    Assignee: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. Farr, Brooks Boyd
  • FORMULATION FOR INHIBITING FORMATION OF 5-HT2B AGONISTS AND METHODS OF USING SAME
    Publication number: 20190083425
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Application
    Filed: November 19, 2018
    Publication date: March 21, 2019
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, BROOKS BOYD
  • FORMULATION FOR INHIBITING FORMATION OF 5-HT2B AGONISTS AND METHODS OF USING SAME
    Publication number: 20190083424
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Application
    Filed: November 16, 2018
    Publication date: March 21, 2019
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, BROOKS BOYD
  • FORMULATION FOR INHIBITING FORMATION OF 5-HT2B AGONISTS AND METHODS OF USING SAME
    Publication number: 20180055789
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Application
    Filed: August 2, 2017
    Publication date: March 1, 2018
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, BROOKS BOYD